Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL3824232 | 0.81 | — | — | |
| Isobutyraldehyde SCHEMBL9790327 | 0.81 | — | — | |
| SCHEMBL1046368 | 0.80 | — | — | |
| SCHEMBL4536370 | 0.80 | — | — | |
| SCHEMBL209653 | 0.80 | — | — | |
| Acetaldehyde SCHEMBL1401397 | 0.78 | TSHR (0.43) | — | |
| SCHEMBL3207667 | 0.78 | ALDH1A1 (0.36) | — | |
| Acetaldehyde SCHEMBL225414 | 0.78 | — | — | |
| SCHEMBL5618574 | 0.78 | — | — | |
| Iodide SCHEMBL23540723 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468727-A1 | Pyridine and pyrimidine derivatives as MGLUR2 antagonists | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8183262-B2 | Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine | HOFFMANN-LA ROCHE INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7772286-B2 | Polyvinyl alcohol copolymers comprising biomolecules | EYESENSE AG (CH) | 2010-08-10 | — | — | US | disclosed |
| US-7642264-B2 | Phenyl-substituted pyrimidine derivatives as mGluR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GATTI MCARTHUR SILVIA | 2009-12-24 | — | — | US | disclosed |
| EP-1599508-B1 | COPOLYMERS COMPRISING BIOMOLECULES | EYESENSE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-2001849-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007110337-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-04 | — | — | WO | disclosed |
| US-7273861-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-09-25 | — | — | US | disclosed |
| EP-1599508-A1 | COPOLYMERS COMPRISING BIOMOLECULES | Novartis AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2005-04-14 | — | — | US | disclosed |
| WO-2004076500-A1 | COPOLYMERS COMPRISING BIOMOLECULES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
| US-20040132723-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-07-08 | — | — | US | disclosed |
| US-20040092750-A1 | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1367050-A1 | 2-METHYLINDOLE-4-ACETIC ACID, PROCESS FOR PRODUCING THE SAME, AND PROCESS FOR PRODUCING INTERMEDIATE THEREFOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6642218-B2 | (5Z,7E,22E)-(1S,3R,24R)-25-(5-Propyloxazol-2-yl)-26,27-cyclo -9,10-secocholesta-5,7,10(19), 22-tetraene-1,3,24-triol for treatment of diseases characterized by hyperproliferation and deficient cell differentiation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-04 | — | — | US | disclosed |
| US-6613920-B1 | 25-(5-propylimidazol-2-yl)-26,27-cyclo-9, 10-secocholesta-5,7,10(19),22-tetraene-1,3,24-triol; antagonizes the action of calcitriol in HL 60 cells; hyperprolifierative diseases of the skin, tumor diseases and precancerous stages | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-02 | — | — | US | disclosed |
| US-6600058-B1 | The invention concerns new vitamin D derivatives of general formula (I) a process for their production, their use for production of medicaments, and intermediate products used in the process. treating a patient for hyperprolifierative | SCHERING AKTIENGELLSCHAFT (DE) | 2003-07-29 | — | — | US | disclosed |
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132723-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, POLR2H, NSUN2 | SLC1A3 3016/4885SLC1A2 3681/4885SLC1A1 2860/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | SLC1A3 851/4885SLC1A2 112/4885SLC1A1 566/4885 |
| US-20090318474-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS | GRM2, GRM1, GRM3 | SLC1A3 182/4885SLC1A2 50/4885SLC1A1 120/4885 |
| US-20020049344-A1 | NEW VITAMIN D DERIVATIVES WITH CARBO-OR HETEROCYCLIC SUBSTITUENTS AT C-25, A PROCESS FOR THEIR PRODUCTION, INTERMEDIATE PRODUCTS AND THEIR USE FOR PRODUCING MEDICAMENTS | CYP2R1, VDR, CYP24A1 | SLC1A3 4814/4885SLC1A2 4827/4885SLC1A1 4844/4885 |
| US-20040092750-A1 | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor | TPH2, ALDH7A1, IDO1 | SLC1A3 701/4885SLC1A2 255/4885SLC1A1 674/4885 |
| US-20050080058-A1 | New vitamin D derivatives with carbo-or heterocyclic substituents at C-25, a process for their production, intermediate products and their use for producing medicaments | VDR, CYP24A1, CYP2R1 | SLC1A3 3511/4885SLC1A2 3413/4885SLC1A1 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.